Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions
- PMID: 17136963
- DOI: 10.1081/copd-200053374
Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions
Abstract
The scientific considerations surrounding the estimation of a minimally clinically important difference (MCID) are a myriad and challenging. There are a considerable number of hurdles to overcome. The good news is that there are solutions to virtually every one of the scientific hurdles. This paper intends to set out the issues, identify the challenges, and offer solutions so that the state of the science may move forward. The ultimate outcome of the paper may not be to provide a definitive answer for estimating the MCID in every situation, but it should provide a starting point and advice for a process or set of guidelines that may be followed toward achieving this goal. The paper begins with a brief synthesis of the literature and state of the science at the time of publication. The relationship between the process for determining MCIDs for other endpoints, such as tumor response or complete blood culture (CBC) variables, versus toxicity and QOL-related variables is described. The ultimate lessons to be learned from this exercise are: 1. There are many methods available to ascertaining an MCID. None are perfect, but all are useful. 2. All methods converge to similar answers. Supplementary information may refine answers from one or more of the methods. 3. Clinical opinion and patient subjective response should trump statistical theory. 4. A process of MCID estimation involving all approaches to produce a potential range with sensitivity analyses is the optimal solution to producing an MCID based on the most complete knowledge possible.
Similar articles
-
Challenges associated with estimating minimal clinically important differences in COPD-the NHLBI perspective.COPD. 2005 Mar;2(1):43-6. doi: 10.1081/copd-200050649. COPD. 2005. PMID: 17136960 Review.
-
The minimally clinically important difference in generic utility-based measures.COPD. 2005 Mar;2(1):91-7. doi: 10.1081/copd-200052090. COPD. 2005. PMID: 17136968
-
U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease.COPD. 2005 Mar;2(1):47-9. doi: 10.1081/copd-200050660. COPD. 2005. PMID: 17136961
-
Do we know the minimal clinically important difference (MCID) for COPD exacerbations?COPD. 2013 Apr;10(2):243-9. doi: 10.3109/15412555.2012.733463. Epub 2013 Mar 20. COPD. 2013. PMID: 23514218 Review.
-
Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.Qual Life Res. 2018 Apr;27(4):1089-1098. doi: 10.1007/s11136-017-1745-8. Epub 2017 Nov 29. Qual Life Res. 2018. PMID: 29188483 Clinical Trial.
Cited by
-
'Optimism bias' in contemporary national clinical trial network phase III trials: are we improving?Ann Oncol. 2018 Oct 1;29(10):2135-2139. doi: 10.1093/annonc/mdy340. Ann Oncol. 2018. PMID: 30412223 Free PMC article.
-
What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients?Laryngoscope. 2016 May;126(5):1108-13. doi: 10.1002/lary.25778. Epub 2015 Nov 6. Laryngoscope. 2016. PMID: 26542529 Free PMC article.
-
The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea.J Palliat Med. 2013 Aug;16(8):881-6. doi: 10.1089/jpm.2012.0591. Epub 2013 Jun 8. J Palliat Med. 2013. PMID: 23746231 Free PMC article.
-
Testing the effectiveness and implementation of a brief version of the Common Elements Treatment Approach (CETA) in Ukraine: a study protocol for a randomized controlled trial.Trials. 2018 Aug 3;19(1):418. doi: 10.1186/s13063-018-2752-y. Trials. 2018. PMID: 30075806 Free PMC article.
-
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.Lancet Oncol. 2020 Jun;21(6):851-860. doi: 10.1016/S1470-2045(20)30081-4. Lancet Oncol. 2020. PMID: 32502445 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical